Abstract: The present invention provides an encapsulated gas or partial vacuum particle contrast media for use in CT imaging. In an exemplary embodiment, the invention provides an enteric contrast medium formulation. An exemplary formulation comprises, (a) an enteric contrast medium comprising a encapsulated gas or partial vacuum particle suspended in water. Exemplary encapsulated gas or partial vacuum particle has a specific gravity between 0.2 and 1.5. In various embodiments, the encapsulated gas or partial vacuum particle is suspended in aqueous media by an agent compatible with enteric administration of the formulation to a subject in need of such administration. In an exemplary embodiment, the contrast material is incorporated into a pharmaceutically acceptable carrier in which the material is suspended homogeneously. In an exemplary embodiment, the encapsulated gas or partial vacuum particle comprises 5% or more of the weight of the contrast material formulation.

Abstract: Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

Abstract: Methods of treating neuroinflammation in a subject by administering to the subject an agent that inhibits activation of coagulation factor XI (FXI), inhibits the activity of activated FXI (FXIa), or reduces expression of FXI are described. The agent that inhibits activation of FXI can be a monoclonal antibody specific for FXI, such as a monoclonal antibody having the complementarity determining region (CDR) sequences of anti-FXI antibody 14E11. Small molecule inhibitors and antisense compounds directed to FXI or FXIa are also contemplated as agents that inhibit activity of FXIa or reduce expression of FXI. The neuroinflammation in the subject can be associated with any one of a number of different diseases or disorders, such as an autoimmune disease of the central nervous system (CNS) or a neurodegenerative disease.

Abstract: The present invention provides methods of treating mycobacterial infections or mycobacterial diseases by administering a tetracycline compound, e.g., omadacycline, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides compounds of Formula (VIIb) and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.

Abstract: The present disclosure relates to a non-transitory computer-readable medium storing computer-executable instructions that, when executed, cause a processor to perform operations, including generating an imaging data set having both scan data and digitized biopsy data from a patient with small cell lung cancer (SCLC). Scan derived features are extracted from the scan data and biopsy derived features are extracted from the digitized biopsy data. A radiomic-pathomic risk score (RPRS) is calculated from one or more of the scan derived features and one or more of the biopsy derived features. The RPRS is indicative of a prognosis of the patient.

Abstract: A sensing device can be used for ambulatory urodynamics. The sensing device can include an elongated outer housing constructed of flexible material that can curve within a patient's bladder. At least a portion of the outer housing can be filled with a non-compressible fluid. A flexible printed circuit board can be disposed within the outer housing to curve with the outer housing. The printed circuit board can include a pressure sensor, comprising a diaphragm, to collect pressure data; a microcontroller running control software; and a wireless transmitter to transmit the pressure data. A battery can be disposed within the outer housing and coupled to the printed circuit board. The flexible material of the outer housing is configured to be displaced by a pressure within the patient's bladder, the displacement is transmitted through the non-compressible fluid to the pressure sensor that provides the pressure data based on the displacement.

Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistence to the treatment, prevention, and diagnosis of diseases/symptoms induced by multiple myeloma. Embodiments include methods of treating a bone related disease, comprising the steps of: administering to a subject at least one therapeutically effective dose of a compound disclosed herein.

Abstract: Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

Abstract: A method of treating an ocular disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a retinal sequestering compound of formula (I).

Abstract: The present disclosure is concerned with magneto-patterned cell-laden hydrogel materials and methods of making and using those materials. The disclosed materials are useful for, among other things, repair of tissue defects, e.g., tissue at a tissue interface such as a bone-cartilage interface.

Abstract: A guide system is provided that uses a plurality of sensors to identify and determine a clear path for an ambulatory vision impaired person. The system includes one or more wheels that rotate to propel the system, a platform supported by the one or more wheels and housing a processor, a rigid harness with a haptic feedback grip that is positioned to be grasped by an operator, and one or more sensors configured to sense information about the environment. In operation, the processor analyzes information sensed by the sensors to identify object in the path of the guide system and sends messages to the operator to allow the operator to avoid the identified objects. The messages may be sent to the operator via the haptic feedback grip or audibly via a speaker or via a wireless connection to a haptic or audio device being worn by the operator.

Abstract: The present invention concerns protection of an organ or tissue outside of the central nervous system following an ischemic episode. In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth. In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1. Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example.

Abstract: Disclosed herein, are decoy peptides or polypeptides capable of inhibiting binding of 5-HT2A autoantibodies to a second extracellular loop region of the 5-HT2A receptor, and a pharmaceutical composition containing the decoy peptides or polypeptides and methods of use.

Abstract: The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target.

Abstract: An assembly for receiving a transesophageal echocardiogram (TEE) probe comprising a probe shaft having a length can comprise a cover defining an opening at a proximal end and a receiving space in communication with the opening, the receiving space having a length in a longitudinal dimension that is sufficient to receive the length of the probe shaft. A gel capsule can be positioned within the receiving space of the cover. The gel capsule can define a proximal opening and an interior in communication with the proximal opening. The interior of the gel capsule can contain a quantity of gel. Within a plane that is perpendicular to the longitudinal dimension, the interior can have a cross sectional area that is sufficient to receive a distal end of the probe shaft with a clearance to permit contact between the gel within the capsule and an exterior surface of the probe shaft.

Abstract: Provided herein are, for example, systems and methods of diagnosing and treating depression, in which a transcranial magnetic stimulation (TMS) therapy is administered to a subject in need thereof and measuring a TMS evoked response in the subject, are provided. The systems and methods allow tailoring or optimizing of a treatment protocol for maximal individual benefit, thereby providing an individualized and optimized treatment protocol for psychiatric disorders such as depression.

Abstract: Disclosed are compositions, devices, kits, and methods for treatment of Enterobacteriaceae infection. Aspects of the present disclosure are directed to bacteriophage compositions comprising one or more of ES17, ES19, HP3, HP3.1, and HP3.2. Certain aspects of the disclosure are directed to compositions comprising (a) bacteriophage ES17 or bacteriophage ES19, (b) bacteriophage HP3, and (c) bacteriophage HP3.1. Also disclosed are compositions comprising bacteriophage HP 3.2. Further disclosed are devices and kits comprising such compositions and methods for use of such compositions in treatment and prevention of pathogenic E. coli infection.

Abstract: Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

Abstract: Disclosed herein are methods of treating disorders of the retina (e.g., macular degeneration, retinitis pigmentosa, etc.) comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound (for example, an antipsychotic drug) that blocks or diminishes agonist-mediated responses upon binding to either dopamine D2-like receptors or serotonin 5-HT2 receptors.